BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] traded at a high on 05/17/21, posting a 11.99 gain after which it closed the day’ session at $14.38. The company report on May 12, 2021 that BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for oral, once-daily ORLADEYO™ (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in HAE patients 12 years and older.
“HAE UK welcomes the decision from the MHRA to grant marketing authorization for berotralstat in the UK. Hereditary angioedema is an unpredictable and life-threatening condition which causes significant emotional and economic burdens on people with HAE and their families and careers. These burdens negatively impact their mental health and well-being, on top of the physical demands of living with a chronic condition. An oral therapy that shows effective control of HAE attacks will provide a different treatment choice for clinicians and patients and will assist in improving the quality of life of those living with the condition,” said Laura Szutowicz, chief executive officer of HAE UK.
The results of the trading session contributed to over 7457855 shares changing hands. Over the past one week, the price volatility of BioCryst Pharmaceuticals Inc. stands at 9.41% while the volatility over the past one month is 7.48%.
The market cap for BCRX stock reached $2.38 billion, with 177.34 million shares outstanding and 176.15 million shares in the current float. Compared to the average trading volume of 5.50M shares, BCRX reached a trading volume of 7457855 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about BioCryst Pharmaceuticals Inc. [BCRX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $14.56 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 01, 2021. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on September 29, 2020, representing the official price target for BioCryst Pharmaceuticals Inc. stock.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.92, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 74.38.
How has BCRX stock performed recently?
BioCryst Pharmaceuticals Inc. [BCRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.54. With this latest performance, BCRX shares gained by 27.94% in over the last four-week period, additionally plugging by 238.35% over the last 6 months – not to mention a rise of 171.83% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 66.03, with the RSI for the last a single of trading hit 70.14, and the three-weeks RSI is set at 63.11 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 11.58, while it was recorded at 12.76 for the last single week of trading, and 7.48 for the last 200 days.
BioCryst Pharmaceuticals Inc. [BCRX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -952.90 and a Gross Margin at +90.59. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -1026.35.
Return on Total Capital for BCRX is now -131.36, given the latest momentum, and Return on Invested Capital for the company is -195.22. Return on Equity for this stock declined to -1,925.37, with Return on Assets sitting at -71.69. Additionally, BCRX Total Debt to Total Capital is recorded at 114.21, with Total Debt to Total Assets ending up at 46.24.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$743,146 per employee. Receivables Turnover for the company is 1.16 with a Total Asset Turnover recorded at a value of 0.07.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.
Earnings analysis for BioCryst Pharmaceuticals Inc. [BCRX]
With the latest financial reports released by the company, BioCryst Pharmaceuticals Inc. posted -0.24/share EPS, while the average EPS was predicted by analysts to be reported at -0.25/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
Insider trade positions for BioCryst Pharmaceuticals Inc. [BCRX]
There are presently around $1,505 million, or 68.70% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 16,241,775, which is approximately -0.111% of the company’s market cap and around 0.80% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 12,710,818 shares of the stock with an approximate value of $182.78 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $139.49 million in BCRX stock with ownership of nearly -16.374% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 100 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 18,407,142 shares. Additionally, 99 investors decreased positions by around 34,158,056 shares, while 19 investors held positions by with 52,065,743 shares. The mentioned changes placed institutional holdings at 104,630,941 shares, according to the latest SEC report filing. BCRX stock had 45 new institutional investments in for a total of 11,542,069 shares, while 30 institutional investors sold positions of 7,623,907 shares during the same period.